Cabozantinib for High-Risk Pediatric Solid Tumors
This study is testing a drug called cabozantinib maleate to see if it can prevent cancer from coming back or getting worse in children and young adults with certain high-risk solid tumors, specifically neuroblastoma and sarcoma. You might be able to join if you are between 18 months and 40 years old and have already had treatment for your cancer with a good response. The study aims to see if taking cabozantinib daily for up to 12 months can improve the chance of staying cancer-free for at least one year. This research is important because these types of cancers often come back and there are not many good treatment options when they do.
- Study design
- This interventional study plans to enroll 86 participants. The phase of the study is not specified.
- What's involved
- You would take cabozantinib maleate tablets daily for up to 12 months, in 28-day cycles.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main goal is measured at 4 years, suggesting follow-up for at least that long after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
At a glance
Conditions
Where it's being run
6 sites across 6 statesStudy leadership
- Nilay Shah, MD · PRINCIPAL_INVESTIGATOR · Nationwide Children's Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the effect of oral daily cabozantinib, administered for up to 12 months, on the one-year progression-free survival of patients with "ultra-high-risk" pediatric solid tumors.4 years
Defined as the time from diagnosis until the date of disease progression